v3.26.1
Commitments and Contingencies - Additional Information (Details)
$ in Thousands, € in Millions, £ in Millions
3 Months Ended
Jan. 08, 2025
USD ($)
Mar. 31, 2026
USD ($)
Mar. 31, 2025
USD ($)
Jan. 31, 2024
GBP (£)
Feb. 28, 2021
EUR (€)
Gain Contingencies [Line Items]          
Research and development Expense   $ 9,373 $ 17,327    
Increase decrease in operating lease liability   (62) (59)    
ProBioGen Agreement [Member] | Manufacturing Services [Member]          
Gain Contingencies [Line Items]          
Milestone Payment, Amount Reduced   1,200     € 1.1
Mabworks Agreement [Member]          
Gain Contingencies [Line Items]          
Upfront Payment Paid $ 9,000        
Maximum [Member] | ProBioGen Agreement [Member] | Sales Milestones [Member]          
Gain Contingencies [Line Items]          
Milestone Payments   8,000     7.0
Development Regulatory and Commercial Milestones [Member] | Maximum [Member] | Acelyrin Asset Purchase Agreement [Member]          
Gain Contingencies [Line Items]          
Milestone Payments   157,500      
Development and Regulatory Milestones [Member] | Mabworks Agreement [Member]          
Gain Contingencies [Line Items]          
Milestone Payments 30,000        
Development Regulatory Commercial and Sales Milestones Member] | Maximum [Member] | CRH Agreement [Member]          
Gain Contingencies [Line Items]          
Milestone Payments   141,200   £ 106.8  
Development Manufacturing and Commercial [Member] | Maximum [Member] | ProBioGen Agreement [Member]          
Gain Contingencies [Line Items]          
Milestone Payments   $ 11,500     € 10.0
Commercial Milestones [Member] | Mabworks Agreement [Member]          
Gain Contingencies [Line Items]          
Milestone Payments $ 832,000        
Research and Development Expense [Member] | Mabworks Agreement [Member]          
Gain Contingencies [Line Items]          
Upfront Payment Paid     $ 9,000